ArticleJournal of experimental & clinical cancer research : CR2026
Unbiased profiling of translational landscape reveals TNFR2 as a translation-dependent vulnerability in colorectal cancer.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranslational dysregulation plays a key role in tumour initiation and progression, including in colorectal cancer (CRC). However, the mechanisms underlying translational control and the systematic characterization of translation-dependent vulnerabilities remain poorly understood in CRC.
methodsWe profiled 34 colorectal tissue samples to define a comprehensive translatomic landscape of CRC, uncovering a set of unannotated ORFs from coding (both in-frame and out-of-frame) and long noncoding RNAs (lncRNAs). Additionally, we delineated five translatomic clusters that significantly correlated with specific clinical features and common CRC mutations.
resultsFurther analysis revealed a functionally coherent network of 449 genes that are exclusively regulated at the translational level and specifically promote CRC progression by modulating cell growth and immune responses. Among these, tumour necrosis factor receptor 2 (TNFR2) stood out as the most promising vulnerability with significant translational activation in CRC. Pharmacological inhibition of TNFR2 suppressed tumorigenesis in both cell-based and organoid models, and was further validated in vivo using patient-derived organoid xenograft (PDOX) models.
conclusionOur study establishes a systematic framework bridging unbiased translatome discovery to functional validation, in which we identified and functionally validated the therapeutic vulnerability of translationally activated TNFR2 in CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.